sNDA and sBLA Pipeline - 2H 2026

IPD Analytics has released its sNDA and sBLA Drug Pipeline Report – 2H 2026, featuring analysis on 18 key drugs poised for potential FDA approval for new or expanded indications over the next 6+ months. The report covers 14 approvals anticipated in new indications, 5 anticipated to expand current labeling, and 2 anticipated for new product presentation. While not intended to be an exhaustive list of all upcoming submissions, these supplemental New Drug Applications (sNDAs) and Biologics License Applications (sBLAs) may carry important clinical and market access implications for managed care stakeholders.

For each product in the report, our experts include a clinical summary, expected place in therapy, and comparative pricing insights to support informed formulary decision-making.

Complete with a timeline of upcoming PDUFA dates for select drugs with sBLA and sNDA submissions, the report helps payers track these approvals and proactively prepare for P&T committee reviews, update coverage policies, and assess any necessary adjustments to management strategies.

Use this report as a companion to IPD’s Clinical Development Tracker, which provides up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas. In tandem, these reports deliver insight into trending classes that will affect the competitive landscape and your drug spend.

Content on this site is proprietary to IPD Analytics. This sample is not for distribution. By receiving it, you agree to refrain from any unauthorized use, including uploading or inputting it into AI tools or large language models (LLMs) for training or any other purpose. This is strictly prohibited.